Vanessa de Almeida Belo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Vanessa de Almeida Belo has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Carla Márcia Moreira Lanna
Institute of Biological Sciences, Federal University of Juiz de Fora, Juiz de Fora, MG, Brazil
4 shared publicationsJosiane Aparecida de Miranda
Methodist College Granbery, Juiz de Fora, MG, Brazil
4 shared publications- Marcelo Rizzatti Luizon
Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil
3 shared publications Riccardo Lacchini
University of São Paulo at Ribeirão Preto School of Nursing, Ribeirão Preto, SP, Brazil
3 shared publications- Warlley Rosa Cunha
Center for Molecular Genetics and Genomics, Wayne State University, Detroit, MI, USA
3 shared publications Beatriz Cazarim de Souza
School of Medicine, Barbacena, Brazil
2 shared publications
Latest Publications
- 31 March 2026
- Published by Elsevier in Archives of Medical Research
- Vol. 57 (5) , 103413
ADIPOQ Genotypes, Adiponectin Isoforms, and Hypertension Risk in Pediatric Obesity
- 31 March 2026
- Published by Elsevier in Archives of Medical Research
- Vol. 57 (5) , 103413
ADIPOQ Genotypes, Adiponectin Isoforms, and Hypertension Risk in Pediatric Obesity
- 25 January 2025
- Published by Elsevier in Clinical Biochemistry
- Vol. 136, 110889
Oxidative stress and obesity are associated with endothelial dysfunction and subclinical atherosclerosis in adolescents
- 25 January 2025
- Published by Elsevier in Clinical Biochemistry
- Vol. 136, 110889
Oxidative stress and obesity are associated with endothelial dysfunction and subclinical atherosclerosis in adolescents
- 28 April 2023
- Published by Springer Nature in Reproductive Sciences
- Vol. 30 (10) , 2893-2895
Longitudinal Study of Plasma Visfatin/Nicotinamide Phosphoribosyltransferase (NAMPT) Levels in Healthy Pregnant Women
Visfatin/nicotinamide phosphorybosil transferase (NAMPT) is a novel adipocytokine with potential roles in the pathophysiology of metabolic disorders, including gestational disorders. However, there is no clear interpretation regarding the circulating visfatin levels in a healthy pregnancy. Therefore, we conducted the first longitudinal study of plasma visfatin levels that followed up healthy pregnant women until the third trimester, including the postpartum period (PPP). The study recruited healthy women with singleton pregnancy who were not using any drug (including tobacco and alcohol). We have excluded pregnant women who did not attend all scheduled exams and developed gestational diabetes or hypertension, obesity, preeclampsia, or any infections during pregnancy. Nine women were considered eligible and examined during all three trimesters of pregnancy and between 8 and 12 weeks postpartum (PPP). Visfatin/NAMPT concentrations were measured in EDTA-plasma by ELISA. The mean age of pregnant women included was 22±5 years (54% primiparous), and the mean of gestational age at delivery was 40±1.2 weeks. Mean systolic and diastolic blood pressures were 90 and 70 mmHg, respectively. Mean values (± standard error mean) of visfatin concentrations (μg/L) during trimesters were 11.38±1.45 (first, 11–14 weeks), 9.18±1.82 (second, 20–24 weeks), 18.67±2.65 (third, 34–36 weeks), and 10.12±1.49 in the PPP. The value of the third trimester was significantly higher than the second trimester, and significantly reduced in the PPP (p<0.05, ANOVA with Bonferroni’s multiple comparison tests). Visfatin/NAMPT levels are significantly lower in the PPP, suggesting that factors stimulating its production would be limited to pregnancy, thereby contributing to its potential application as a biomarker in pregnancy complications.
- 28 April 2023
- Published by Springer Nature in Reproductive Sciences
- Vol. 30 (10) , 2893-2895
Longitudinal Study of Plasma Visfatin/Nicotinamide Phosphoribosyltransferase (NAMPT) Levels in Healthy Pregnant Women
Visfatin/nicotinamide phosphorybosil transferase (NAMPT) is a novel adipocytokine with potential roles in the pathophysiology of metabolic disorders, including gestational disorders. However, there is no clear interpretation regarding the circulating visfatin levels in a healthy pregnancy. Therefore, we conducted the first longitudinal study of plasma visfatin levels that followed up healthy pregnant women until the third trimester, including the postpartum period (PPP). The study recruited healthy women with singleton pregnancy who were not using any drug (including tobacco and alcohol). We have excluded pregnant women who did not attend all scheduled exams and developed gestational diabetes or hypertension, obesity, preeclampsia, or any infections during pregnancy. Nine women were considered eligible and examined during all three trimesters of pregnancy and between 8 and 12 weeks postpartum (PPP). Visfatin/NAMPT concentrations were measured in EDTA-plasma by ELISA. The mean age of pregnant women included was 22±5 years (54% primiparous), and the mean of gestational age at delivery was 40±1.2 weeks. Mean systolic and diastolic blood pressures were 90 and 70 mmHg, respectively. Mean values (± standard error mean) of visfatin concentrations (μg/L) during trimesters were 11.38±1.45 (first, 11–14 weeks), 9.18±1.82 (second, 20–24 weeks), 18.67±2.65 (third, 34–36 weeks), and 10.12±1.49 in the PPP. The value of the third trimester was significantly higher than the second trimester, and significantly reduced in the PPP (p<0.05, ANOVA with Bonferroni’s multiple comparison tests). Visfatin/NAMPT levels are significantly lower in the PPP, suggesting that factors stimulating its production would be limited to pregnancy, thereby contributing to its potential application as a biomarker in pregnancy complications.
- 17 April 2023
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 182 (6) , 2925-2931
High molecular weight adiponectin as a biomarker of hypertension in children and adolescents with obesity
Lower HMW (high molecular weight) adiponectin levels are associated with obesity, insulin resistance, and metabolic syndrome in children and adolescents. However, data on HMW levels in pediatric population with hypertension are lacking. This study aimed to examine the association and predictive capacity of HMW levels, HMW/HOMA-IR, and HMW/APN ratio with hypertension in obese children and adolescents. The 299 pediatric subjects were grouped in obese hypertensive (OH), obese normotensive (ON), and normal weight normotensive (NN). Plasma concentrations of HMW were investigated by ELISA. ANOVA was used to compare study groups, and a binary logistic regression analysis was used to verify if HMW, HMW/HOMA-IR, HMW/APN, APN, APN/HOMA-IR, and HOMA-IR are associated to hypertension regardless obesity in children and adolescents. To compare the strength and performance of each biomarker to classify individuals with and without hypertension, the receiver-operating characteristic (ROC) curve, area under the curve (AUC), and Youden index (J) were evaluated. Both HMW plasma levels and the HMW/HOMA-IR ratio were significantly lower in the OH group when compared to the ON group (HMW: 2.00 ± 1.33 µg/mL vs 2.48 ± 1.48 µg/mL; HMW/HOMA-IR ratio: 0.87 ± 0.95 vs 1.27 ± 1.2; P < 0.05) and NN weight groups (HMW: 2.00 ± 1.33 µg/mL vs 4.02 ± 1.99 µg/mL; HMW/HOMA-IR ratio: 0.87 ± 0.95 vs 2.62 ± 1.86; P < 0.05). Hypertension was associated with lowest HMW (OR = 4.50; 95% CI = 1.41–15.84) and HMW/HOMA-IR (OR = 12.13; 95% CI = 2.51–92.93) regardless of obesity. However, HOMA-IR or the HMW/APN was not significant (P > 0.05). In the ROC curve analyses, the HMW and HMW/HOM-IR were more sensitive to detect hypertension in children and adolescents with obesity. Conclusion: Low levels of HMW oligomer and HMW/HOM-IR are associated with hypertension in childhood obesity. Thus, these biomarkers could be clinically useful in identifying hypertension in childhood obesity. What is Known: • HMW has previously been reported as the most biologically active isoform of adiponectin, and lower HMW concentrations are associated with obesity, insulin resistance, and metabolic syndrome in children and adolescents. • HMW/HOMA-IR ratio is a sensitive predictor for metabolic syndrome in adults. What is New: • HMW levels are associated with hypertension in children and adolescents, independently of presence of obesity. • HMW was more sensitive to detect hypertension in children and adolescents with obesity when compared to HMW/HOMA-IR, HMW/APN, APN, APN/HOMA-IR, or HOMA-IR.
- 17 April 2023
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 182 (6) , 2925-2931
High molecular weight adiponectin as a biomarker of hypertension in children and adolescents with obesity
Lower HMW (high molecular weight) adiponectin levels are associated with obesity, insulin resistance, and metabolic syndrome in children and adolescents. However, data on HMW levels in pediatric population with hypertension are lacking. This study aimed to examine the association and predictive capacity of HMW levels, HMW/HOMA-IR, and HMW/APN ratio with hypertension in obese children and adolescents. The 299 pediatric subjects were grouped in obese hypertensive (OH), obese normotensive (ON), and normal weight normotensive (NN). Plasma concentrations of HMW were investigated by ELISA. ANOVA was used to compare study groups, and a binary logistic regression analysis was used to verify if HMW, HMW/HOMA-IR, HMW/APN, APN, APN/HOMA-IR, and HOMA-IR are associated to hypertension regardless obesity in children and adolescents. To compare the strength and performance of each biomarker to classify individuals with and without hypertension, the receiver-operating characteristic (ROC) curve, area under the curve (AUC), and Youden index (J) were evaluated. Both HMW plasma levels and the HMW/HOMA-IR ratio were significantly lower in the OH group when compared to the ON group (HMW: 2.00 ± 1.33 µg/mL vs 2.48 ± 1.48 µg/mL; HMW/HOMA-IR ratio: 0.87 ± 0.95 vs 1.27 ± 1.2; P < 0.05) and NN weight groups (HMW: 2.00 ± 1.33 µg/mL vs 4.02 ± 1.99 µg/mL; HMW/HOMA-IR ratio: 0.87 ± 0.95 vs 2.62 ± 1.86; P < 0.05). Hypertension was associated with lowest HMW (OR = 4.50; 95% CI = 1.41–15.84) and HMW/HOMA-IR (OR = 12.13; 95% CI = 2.51–92.93) regardless of obesity. However, HOMA-IR or the HMW/APN was not significant (P > 0.05). In the ROC curve analyses, the HMW and HMW/HOM-IR were more sensitive to detect hypertension in children and adolescents with obesity. Conclusion: Low levels of HMW oligomer and HMW/HOM-IR are associated with hypertension in childhood obesity. Thus, these biomarkers could be clinically useful in identifying hypertension in childhood obesity. What is Known: • HMW has previously been reported as the most biologically active isoform of adiponectin, and lower HMW concentrations are associated with obesity, insulin resistance, and metabolic syndrome in children and adolescents. • HMW/HOMA-IR ratio is a sensitive predictor for metabolic syndrome in adults. What is New: • HMW levels are associated with hypertension in children and adolescents, independently of presence of obesity. • HMW was more sensitive to detect hypertension in children and adolescents with obesity when compared to HMW/HOMA-IR, HMW/APN, APN, APN/HOMA-IR, or HOMA-IR.
- 4 April 2023
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 24 (5) , 269-281
Effects of ADIPOQ and NOS3 SNPs/haplotypes on Blood Pressure Control in Patients With Adherence to Antihypertensive Therapy
Aim: We examined whether ADIPOQ (rs266729 and rs1501299) and NOS3 (rs3918226 and rs1799983) SNPs or the haplotypes formed by them, affect blood pressure (BP) control in 196 patients with adherence ...
- 4 April 2023
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 24 (5) , 269-281
Effects of ADIPOQ and NOS3 SNPs/haplotypes on Blood Pressure Control in Patients With Adherence to Antihypertensive Therapy
Aim: We examined whether ADIPOQ (rs266729 and rs1501299) and NOS3 (rs3918226 and rs1799983) SNPs or the haplotypes formed by them, affect blood pressure (BP) control in 196 patients with adherence ...
- Open Access
- 21 July 2022
- Published by Springer Nature in Research Square
High molecular weight adiponectin as a biomarker of hypertension in children and adolescents with obesity
Purpose: To investigate the association of High Molecular Weight Adiponectin (HMW), HMW/ Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and HMW/Adiponectin (APN) ratio with hypertension in obese children and adolescents, we evaluated the concentrations of HMW and HMW/APN in the plasma of obese children and adolescents with hypertension. Methods: The 353 pediatric subjects were grouped according to weight and blood pressure. Anthropometric and biochemical parameters were evaluated. Plasma concentrations of APN and HMW were investigated by ELISA. ANOVA was used to compare study groups, and a binary logistic regression analysis was used to verify if HMW, HMW/HOMA-IR, HMW/APN, APN, APN/HOMA-IR, HOMA-IR are predictors of the development of hypertension in children and adolescents. To compare the strength and performance of each biomarker to classify individuals with and without hypertension, the receiver operating characteristic (ROC) curve, area under the curve (AUC) and Youden index (J) were evaluated. Results: Lower HMW and HMW/HOMA-IR levels were associated with hypertension in obese children and adolescents (PConclusion: Low levels of HMW oligomer and HMW/HOM-IR are associated with hypertension in childhood obesity. Thus, theses biomarkers that could be clinically useful in prognosing hypertension in childhood obesity.
- 21 July 2022
- Published by Springer Nature in Research Square
Open AccessHigh molecular weight adiponectin as a biomarker of hypertension in children and adolescents with obesity
Purpose: To investigate the association of High Molecular Weight Adiponectin (HMW), HMW/ Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and HMW/Adiponectin (APN) ratio with hypertension in obese children and adolescents, we evaluated the concentrations of HMW and HMW/APN in the plasma of obese children and adolescents with hypertension. Methods: The 353 pediatric subjects were grouped according to weight and blood pressure. Anthropometric and biochemical parameters were evaluated. Plasma concentrations of APN and HMW were investigated by ELISA. ANOVA was used to compare study groups, and a binary logistic regression analysis was used to verify if HMW, HMW/HOMA-IR, HMW/APN, APN, APN/HOMA-IR, HOMA-IR are predictors of the development of hypertension in children and adolescents. To compare the strength and performance of each biomarker to classify individuals with and without hypertension, the receiver operating characteristic (ROC) curve, area under the curve (AUC) and Youden index (J) were evaluated. Results: Lower HMW and HMW/HOMA-IR levels were associated with hypertension in obese children and adolescents (PConclusion: Low levels of HMW oligomer and HMW/HOM-IR are associated with hypertension in childhood obesity. Thus, theses biomarkers that could be clinically useful in prognosing hypertension in childhood obesity.